Daily Cardiology Research Analysis
Three impactful cardiology papers stood out today: a randomized trial showed epicardial substrate ablation significantly reduces ventricular fibrillation recurrences in Brugada syndrome; a nationwide cohort after PCI supports both ≥50% LDL-C reduction and attaining LDL-C <1.4 mmol/L; and a large GWAS meta-analysis of aortic aneurysm/dissection identified novel loci and mechanistic pathways (elastic fibers, TGF-β) with functional validation.
Summary
Three impactful cardiology papers stood out today: a randomized trial showed epicardial substrate ablation significantly reduces ventricular fibrillation recurrences in Brugada syndrome; a nationwide cohort after PCI supports both ≥50% LDL-C reduction and attaining LDL-C <1.4 mmol/L; and a large GWAS meta-analysis of aortic aneurysm/dissection identified novel loci and mechanistic pathways (elastic fibers, TGF-β) with functional validation.
Research Themes
- Ablation therapy for inherited arrhythmia (Brugada syndrome) with randomized evidence
- Post-PCI lipid target strategy: percent reduction and attained LDL-C levels
- Genetic architecture and mechanisms of aortic aneurysm/dissection
Selected Articles
1. Brugada Syndrome Ablation for the Prevention of Ventricular Fibrillation Episodes (BRAVE).
In this randomized, multicenter trial, epicardial substrate ablation in symptomatic Brugada syndrome significantly reduced ventricular fibrillation events versus control over 3 years (HR 0.288). Most patients remained VF-free after ablation, with a low complication rate, supporting earlier, substrate-guided epicardial ablation in high-risk BrS.
Impact: This is the first randomized evidence that epicardial substrate ablation reduces VF in Brugada syndrome, potentially shifting management beyond ICD-only strategies. It directly informs clinical decision-making for a high-mortality arrhythmia.
Clinical Implications: Consider earlier referral for epicardial substrate mapping and ablation in symptomatic Brugada syndrome patients with ICDs, particularly those with recurrent shocks or VF. Centers should develop expertise in epicardial access and substrate-guided ablation.
Key Findings
- Randomized, multicenter trial (n=52) showed ablation reduced VF events versus control over 3 years (HR 0.288; P=0.0184).
- 83% were VF-free after a single procedure and 90% after repeat ablation among those ablated.
- Safety profile was acceptable with one hemopericardium and no long-term sequelae.
Methodological Strengths
- Prospective randomized, multicenter design with predefined endpoints
- Epicardial electroanatomic mapping guiding substrate-targeted ablation
Limitations
- Open-label design with relatively small sample size and early trial termination
- Generalizability limited to centers with epicardial ablation expertise
Future Directions: Larger randomized trials comparing ablation strategies, timing (first-line versus deferred), and mapping criteria are warranted, including quality-of-life and ICD-shock endpoints and long-term safety.
BACKGROUND: Catheter ablation has emerged as a promising treatment to prevent ventricular fibrillation (VF) in Brugada syndrome (BrS). However, evidence from a prospective, randomized clinical trial is lacking. OBJECTIVE: The Brugada Syndrome Ablation for the Prevention of Ventricular Fibrillation Episodes trial is a prospective, multicenter, 2-arm, randomized (1:1), open-label clinical study designed to evaluate the efficacy and safety of ablation therapy in patients with symptomatic BrS. METHODS: We enrolled patients with symptomatic BrS with an implantable cardioverter-defibrillator. Patients were randomized to ablation therapy or control groups. Ablation targeted arrhythmogenic areas identified through electroanatomical mapping, predominantly at the right ventricular epicardium. The primary outcome was the first occurrence of VF or death. One interim analysis was planned after 50 patients were randomized. RESULTS: Of 67 patients screened, 52 were randomized (25 to ablation, 25 to control, 2 withdrawals), and 15 declined randomizations but remained in a registry (10 chose ablation, 5 opted against ablation). After 3 years of follow-up, the ablation group had significantly fewer VF events than the control group (hazard ratio, 0.288; P = .0184). At the interim analysis, the Data Safety Monitoring Board recommended early trial termination. Among all ablation recipients (including crossovers and registry participants), 83% remained VF free after a single procedure and 90% after a repeat ablation. Complications of ablation included 1 hemopericardium without a long-term sequel. CONCLUSION: Epicardial substrate ablation significantly reduces VF recurrence in patients with symptomatic BrS with implantable cardioverter-defibrillators and seems safe, supporting its potential role as a first-line therapy to prevent recurrent VF in patients with symptomatic BrS.
2. Integrative Genome-wide Association Meta-analysis of Aortic Aneurysm and Dissection Identifies Five Novel Genes.
A meta-GWAS of AAD (11,148 cases; 708,468 controls) identified 24 loci including four novel (PALMD, CRIM1, FRK, HMGA2), prioritized 53 genes, and highlighted arterial cell-specific mechanisms involving elastic fiber biogenesis and TGF-β signaling. Genetic correlations and causal links to BMI, lipids, and pulse pressure were observed, and functional assays supported five novel genes regulating vascular cell function.
Impact: This study delivers a comprehensive genetic map of AAD with novel loci and mechanistic insights validated by functional assays, opening avenues for target discovery and risk stratification.
Clinical Implications: While not immediately practice-changing, the prioritized genes and pathways (elastic fibers, TGF-β) and causal links to modifiable traits (BMI, lipids, pulse pressure) inform precision risk assessment and therapeutic target development.
Key Findings
- Meta-GWAS across AAD subtypes identified 24 susceptibility loci, including novel loci at PALMD (1p21.2), CRIM1 (2p22.2), FRK (6q22.1), and HMGA2 (12q14.3).
- Cell-type analyses implicated arterial tissues; 53 genes were prioritized, emphasizing elastic fiber formation and TGF-β signaling.
- Genetic correlations with cardiovascular diseases and causal associations with BMI, lipid levels, and pulse pressure were observed.
- Five genes (PALMD, CRIM1, FRK, HMGA2, NT5DC1) showed functional support as regulators of smooth muscle and endothelial cell function (ex vivo/in vitro).
Methodological Strengths
- Very large meta-analysis (11,148 cases; 708,468 controls) with internal and external validation
- Integrated multi-approach prioritization and functional ex vivo/in vitro validation
Limitations
- Predominantly European ancestry limits generalizability to other populations
- Functional validation remains preclinical; therapeutic translation requires in vivo studies
Future Directions: Extend to diverse ancestries, perform in vivo mechanistic studies, and translate prioritized targets into drug discovery and gene-informed risk models.
Aortic aneurysm and dissection (AAD) is a multifaceted condition characterized by significant genetic predisposition and a considerable contribution to cardiovascular-related mortality. Previous studies have suggested that AAD subtypes share similar genetic mechanisms, however, these studies investigated the subtypes separately. Here, we performed a large genome-wide association study (GWAS) meta-analysis for AAD by combining its subtypes, including 11,148 cases and 708,468 controls of European ancestry. We identified 24 susceptibility loci, including four novel loci at 1p21.2 (PALMD), 2p22.2 (CRIM1), 6q22.1 (FRK), and 12q14.3 (HMGA2), which were partially validated in both internal and external populations. Cell type-specific analysis highlighted the artery as the most relevant tissue where the susceptibility variants may exert their effects in a tissue-specific manner. By using four approaches, we prioritized 53 genes, reinforcing the importance of elastic fiber formation and transforming growth factor-beta (TGF-β) signaling in the formation of AAD, and suggested potential target drugs for the treatment. Additionally, various cardiovascular diseases were genetically correlated with AAD, and several cardiovascular risk factors [e.g., body mass index (BMI), lipid levels, and pulse pressure] showed causal associations with AAD, underscoring their shared genetic structures and mechanisms underlying the comorbidity. Moreover, five prioritized genes (PALMD, CRIM1, FRK, HMGA2, and NT5DC1) at the novel loci were supported as regulators of smooth muscle and endothelial cell functions through ex vivo and in vitro experiments. Together, these findings enhance our understanding of the genetic architecture of AAD and provide novel insights into future biological mechanism studies and therapeutic strategies.
3. Clinical significance of low-density lipoprotein cholesterol percentage reduction and attained levels after percutaneous coronary intervention.
In 135,877 PCI patients, achieving ≥50% LDL-C reduction was associated with lower MACCE risk regardless of baseline LDL-C. Among those with ≥50% reduction, attaining LDL-C <1.4 mmol/L conferred additional benefit versus 1.4–<1.8 or ≥1.8 mmol/L, supporting aggressive targets post-PCI.
Impact: This very large real-world cohort directly addresses a contentious guideline gap by linking both percent reduction and attained LDL-C thresholds to outcomes, with clear implications for secondary prevention strategies after PCI.
Clinical Implications: Post-PCI lipid management should prioritize both ≥50% LDL-C reduction and attaining LDL-C <1.4 mmol/L when feasible, potentially necessitating high-intensity statins and combination therapy (e.g., ezetimibe, PCSK9 inhibitors).
Key Findings
- Of 135,877 PCI patients, 40.1% achieved ≥50% LDL-C reduction, which was associated with lower MACCE risk.
- Among those with ≥50% reduction, patients attaining LDL-C <1.4 mmol/L had fewer MACCE than those at 1.4–<1.8 or ≥1.8 mmol/L.
- Findings support dual goals: percentage reduction and stringent attained LDL-C targets post-PCI.
Methodological Strengths
- Nationwide cohort with very large sample size and pragmatic real-world generalizability
- Stratification by both percent reduction and attained LDL-C levels
Limitations
- Observational design subject to residual confounding and treatment selection bias
- LDL-C assessment windows (within 3 years before/after PCI) may introduce exposure misclassification
Future Directions: Prospective studies or pragmatic trials testing treat-to-target strategies incorporating both percent reduction and absolute LDL-C thresholds after PCI, including cost-effectiveness across health systems.
BACKGROUND: Differences exist between European and American guideline recommendations regarding targets for low-density lipoprotein cholesterol (LDL-C) levels after percutaneous coronary intervention (PCI), with European guidance advocating for more aggressive reduction to less than 1.4 mmol/L compared with the American guideline, which recommends an LDL-C level of 1.8 mmol/L or greater as the threshold for treatment intensification. We aimed to evaluate clinical outcomes according to percentage reduction of LDL-C levels and to compare the outcomes according to the attained LDL-C levels after PCI. METHODS: This nationwide cohort study included adults in South Korea who underwent PCI and health screening within 3 years before and after PCI. Participants were divided into groups with a reduction of LDL-C levels of less than 50% and of 50% or greater. The group with LDL-C reduction of 50% or greater was stratified into categories of LDL-C level after PCI: less than 1.4 mmol/L, 1.4 to less than 1.8 mmol/L, and 1.8 mmol/L or greater. The primary end point was major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of cardiovascular death, spontaneous myocardial infarction (MI), repeat revascularization, and ischemic stroke. RESULTS: We included 135 877 adult participants. A total of 40.1% achieved a reduction of LDL-C levels of 50% or greater ( INTERPRETATION: Among patients who underwent PCI, those who achieved a reduction in LDL-C levels of 50% or greater had a reduced risk of MACCE, regardless of baseline LDL-C levels. Among patients with a reduction in LDL-C levels of 50% or greater, compared with patients with an LDL-C level less than 1.4 mmol/L after PCI, those with an LDL-C level of greater than 1.8 mmol/L and a level of 1.4 to less than 1.8 mmol/L had an increased risk of MACCE. These findings suggest that while achieving an LDL-C reduction of 50% or greater remains a critical therapeutic goal, targeting LDL-C levels of less than 1.4 mmol/L after PCI may provide additional clinical benefit. TRIAL REGISTRATION: ClinicalTrials.gov, NCT06338956.